Measuring the impact of monoclonal antibody drugs in cancer and rheumatoid arthritis

测量单克隆抗体药物对癌症和类风湿性关节炎的影响

• 批准号: MC_PC_20057
• 负责人: Steven Sacks
• 金额: $ 13.71万
• 依托单位: King's College London
• 依托单位国家: 英国
• 项目类别: Intramural
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MC_PC_20057
• 关键词: Measuring; impact; monoclonal; antibody; drugs

It is now over 40 years since the first mab drugs were approved. Today six out of ten of the best selling drugs in the world are mab therapeutics. Mab drugs currently make up a third of all introduced new treatments. Despite their success, no systematic study has been done to assess how many millions of patients have taken such drugs and the extent to which they have benefited their lives. The goal of this project is to determine the impact of the best-selling mAb drugs for cancer and rheumatoid arthritis, two key disease areas where such therapy has had some of its most profound impact. In this study we will measure benefit in terms of clinical benefit (life extension and quality improvement). Previous studies have estimated benefit for a limited number of patients in a given trial. In this project we propose to multiply the estimated benefits by the number of users over a specified period.

自第一批单抗药物获批以来，已经过去了40多年。今天，世界上十分之六的畅销药物是单抗治疗药物。单克隆抗体药物目前占所有新疗法的三分之一。尽管这些药物取得了成功，但还没有进行系统的研究来评估有多少百万患者服用了这些药物，以及这些药物在多大程度上使他们的生活受益。该项目的目标是确定最畅销的mAb药物对癌症和类风湿性关节炎的影响，这两个关键疾病领域的这种治疗产生了一些最深远的影响。在本研究中，我们将从临床获益（寿命延长和质量改善）方面衡量获益。先前的研究估计了特定试验中有限数量患者的获益。在本项目中，我们建议将估计收益乘以特定时期内的用户数量。